NASDAQ: PPCBPropanc Biopharma Inc Stock
$1.70+1.63 (+2,329%)
Updated May 15, 2026
PPCB Price
$1.70
Fair Value Price
N/A
Market Cap
$96.83M
52 Week Low
$0.07
52 Week High
$9.36
P/E
0.07x
P/B
9.85x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$18.36M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.36
Operating Cash Flow
-$4M
Beta
-23.37
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PPCB Overview
Propanc Biopharma, Inc., a biopharmaceutical company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PPCB's potential to beat the market
- PPCB doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PPCB
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $228.77 | A | |
| $50.13 | A | |
| $1.98 | A |
Be the first to know about important PPCB news, forecast changes, insider trades & much more!
PPCB News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PPCB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PPCB was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PPCB is good value based on its earnings relative to its share price (0.07x), compared to the US market average (22.67x)
P/E vs Market Valuation
PPCB is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more PPCB due diligence checks available for Premium users.
Valuation
PPCB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0.07x
Industry
16.9x
Market
22.67x
PPCB is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PPCB is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
PPCB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
9.85x
Industry
4.83x
PPCB is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PPCB's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.4M
Profit Margin
0%
PPCB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$14.3M
Liabilities
$3.5M
Debt to equity
0.36
PPCB's short-term assets ($8.22M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PPCB's short-term assets ($8.22M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PPCB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.1M
Investing
-$154.0
Financing
$981.6k
PPCB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PPCB vs Biotech Stocks
Propanc Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.